Cycling 0 miles
Cycling 372 miles
Cycling 50
Cycling 11.66 miles
Cycling 379.33 miles
Cycling 2697.31 miles
Today
88° 81°
|
Fri
88° 81°
|
Sat
86° 80°
|
Sun
85° 80°
|
If nothing else I am as determined as I am stubborn to give up!
It's time to stop dreaming and begin pursuing!
Here is the official crowdfunding page to support my run across America! Any help small or large will be greatly appreciated.
Want to be void of any criticism then....
Do nothing, Be nothing!
Welcome back my friends to the show that never ends......
Currently averaging 70 miles a week running. I must stay speed wise as if I am on the run across America NOW! No more then 5mph and no slower then 4mph. During the run there will be days I run entire day's worth of miles. Other days run 2 hours, eat and repeat 3 more times. Bout 36 miles. Elevation, weather will play a part. I have started jogging up 30 flights of stairs. Going for runs mid day for intense heat. I am doing my part to prepare, who is going to do their part and help!
I will not turn back from the starting line, I do not fear what others tell me I am unable to accomplish. Back seat drivers, arm chair quarterbacks bring it on!!!!
After posting this I have not heard from my brother......
Signs Of Alcoholism
Friends or family tell you that they’re concerned with your drinking
Dangerous alcohol driven behavior like drinking and driving
Becoming angry or violent while drinking
You miss work because of alcohol
You drink at work
No longer enjoy sober activities that used to bring you pleasure
You can’t just limit yourself to “1″ drink without being miserable
You experience physical withdrawal symptoms when you don’t drink
You hide your drinking from those around you
You can't mistake the sound of thunder, nor my feet running with a purpose. Time to chew some asphalt!
Preparing for summer 2017
Looking forward to staying hydrated during my training and event next summer when I will be running across America! #drinkrehydrate
Check it out....
being informed by a distant Zulu
a moment in time.
was only the reality of my limited
I was young and my life benign.
defined by mystery where these occurrences
where the examined life finds it’s truth.
destiny and poetry
to control my destiny, now I write to find it’s path.
for something others are dying from,
wage, comfort for their suffering,
knowing full well the consequences of my actions
or even the success of your crusade
I am willing to run across America.
(CNN)There is really just one salient question when it comes to today's decision by the Drug Enforcement Administration to expand the number of growers of research-grade marijuana, while still not changing the scheduling of marijuana: Will this decision make it significantly easier for scientists to study the medical benefits of marijuana?
Contradictory policy
Highlights from the Hill
August 2016
In this Issue
- DEA Won’t Reschedule Cannabis to Improve Access for Research
- Amtrak Settles Epilepsy Discrimination Case
DEA Won’t Reschedule Cannabis to Improve Access for Research
On Thursday, August 11, 2016 the Drug Enforcement Agency (DEA) announced it would not reschedule cannabis, but would expand the number of sites that can grow cannabis for research. We are disappointed with the announcement because removing cannabis from Schedule I in the Controlled Substances Act would paved the way for new treatments as well as much needed information that can help families make informed choices about medical cannabis.
We are encouraged that the DEA is considering expanding the number of sites that can grow cannabis for research and will closely monitor the implementation of the proposed expansion. Expansion criteria should not be so burdensome and it does not lead to meaningful expansion of growing sites. Currently it is difficult for scientists and researchers to laboratory-based research studies to better understand how cannabinoid compounds might be working in the brain and to organize clinical trials involving cannabis because it is a Schedule I substance and only the National Institute for Drug Abuse (NIDA) can cultivate cannabis for medical research.
While the DEA acknowledged some promise for CBD for epilepsy and seizures, they looked at a limited number of studies -- none in epilepsy or children, and none published since 2013. Recent studies and preliminary findings from clinical trials involving cannabis have shown minimal side effects or abuse potential for CBD when used to treat uncontrolled seizures.
The Epilepsy Foundation will continue to advocate for removing federal barriers to cannabis research and policies that promote innovation for the nearly one million people living with uncontrolled seizures. You can our press release on the DEA announcement at www.epilepsy.com/cannabis.
Amtrak Settles Epilepsy Discrimination Case
The National Railroad Passenger Association, better known as Amtrak, recently settled a disability discrimination lawsuit involving a job applicant with epilepsy. The lawsuit, filed by the Equal Employment Opportunity Commission (EEOC), involved Shawn Moe.
In April 2013, Moe applied for a job as a Machinist Journeyman at Amtrak’s mechanical yard in Seattle, Washington. Amtrak provided a conditional offer of employment, but withdrew the offer after Moe reported a history of epilepsy during a post-offer medical examination. Amtrak cited safety concerns as its justification for withdrawing the offer. However, Amtrak failed to consider that Moe had been seizure free with medication for years and that Moe received clearance from his neurologist, who assessed that he could perform all the duties of the job, including work on machinery and heights.
EEOC filed the lawsuit in August 2015 after attempts to reach a pre-litigation settlement failed. The lawsuit was recently settled through a consent decree, which awards Moe with $112,000 in compensatory damages and lost wages. Amtrak also agreed to implement a modified ADA policy and train its staff on hiring and assessing for reasonable accommodations. This case is a major victory for job applicants and employees with epilepsy.
EEOC’s press release about the settlement can be viewed here.
Earlier news
Congressional Appropriations Bills Suggest Funding for CDC and NIH
On July 14, the House Appropriations Committee approved the fiscal year 2017 Labor, Health and Human Services (LHHS) Appropriations bill, which would provide an increase in several critical research initiatives. We are encouraged that the committee included $33.3 billion for the National Institutes of Health (NIH), $1.25 billion above the fiscal year 2016 enacted level and $2.25 billion above the President’s discretionary budget request. Furthermore, the Brain Research through Application of Innovative Neurotechnologies (BRAIN) Initiative would be funded at $195 million, an increase of $45 million from the previous year.
On June 7, the Senate Committee on Appropriations, Labor, Health and Human Services, Education, and Related Agencies Subcommittee passed their fiscal year 2017 Labor, HHS & Education Appropriations bill, which includes an increase in funding for epilepsy programs at the Centers for Disease Control and Prevention (CDC).
The appropriations bills must be passed by the full House and Senate, respectively, before they can go to conference for Senators and Representatives to compromise on language. The Epilepsy Foundation strongly supports federal funding for epilepsy research and programs, and we will continue to monitor the appropriations process for fiscal year 2017.
Epilepsy Foundation Urges Congress to Support CARERS Act
On July 12, the Epilepsy Foundation joined several other patient organizations in a group letter led by Americans for Safe Access (ASA) to Senators Grassley (IA) and Leahy (VT) and Representatives Pitts (PA) and Green (TX), urging them to bring the Compassionate Access, Research Expansion, and Respect States (CARERS) Act for a committee vote in the Senate Judiciary Committee and the House Energy and Commerce, Health Subcommittee.
The Epilepsy Foundation strongly supports federal cannabis legislation that would lift federal barriers to cannabis research and create safe, legal access to medical cannabis in the states, including the CARERS Act.
You can view the letter and urge your members of Congress to support the CARERS Act at www.epilepsy.com/cannabis.
On June 21, Beatriz Duque Long, senior director government relations at the Epilepsy Foundation, spoke at a briefing where she explained the Foundation’s support of the CARERS Act. Senators Cory Booker (NJ) and Kirsten Gillibrand (NY) also spoke on the importance of passing the CARERS Act and removing federal barriers to research while protecting individuals in states with medical cannabis programs.
Senators and Patient Groups Oppose Changes to Six Protected Classes
Senators Grassley (IA) and Brown (OH) wrote a letter to the Centers for Medicare and Medicaid Services (CMS) opposing the recent recommendations from the Medicare Payment Advisory Commission (MedPAC) which would weaken the six protected classes. Bloomberg News recently highlighted the letter and the dangers of weakening the six protected classes, and featured a quote from Angela Ostrom, our chief legal officer and vice president public policy, reiterating our strong opposition to MedPAC’s recommendations. You can read the article at http://bit.ly/BNACMS.
Legislation Would Weaken Americans with Disabilities Act
H.R. 3765, the ADA Education and Reform Act of 2015, recently passed out of the House Judiciary Committee and now makes its way to the full House. This legislation would eliminate the responsibility of businesses to know their obligations under the Americans with Disabilities Act (ADA) and place the burden of ensuring that businesses remain accessible on people with disabilities. The Epilepsy Foundation strongly opposes this legislation and will continue to monitor the bill as it moved forward.
Recent Comments